TheraRadar

Maruho

Pre-Approval PRO BETA
🔴

Stale Activity

No new clinical trials started in 2+ years. Activity may be declining or company may be focusing on existing programs. Last trial started: 4/20/2022

25
Total Trials
8
Phase 3
15
Phase 2
0
Recruiting
249
Score

Pipeline by Phase

Phase 3
8
Phase 2
15
Phase 1
3

Therapeutic Focus

Rosacea Atopic Dermatitis Herpes Simplex Cutaneous Common Warts Acne Vulgaris

Clinical Trials (25)

NCT01959295 Phase 3 COMPLETED

Phase III Study of ASP2151 in Herpes Simplex Patients

Started: 8/1/2013

NCT02209324 Phase 3 COMPLETED

Open-label Study of ASP2151 in Herpes Simplex Patients

Started: 11/1/2013

NCT03259620 Phase 3 COMPLETED

A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

Started: 10/30/2017

NCT02971891 Phase 3 COMPLETED

A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

Started: 1/1/2017

NCT02547441 Phase 3 COMPLETED

Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

Started: 12/1/2015

NCT02576860 Phase 3 COMPLETED

Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

Started: 10/1/2015

NCT02576847 Phase 3 COMPLETED

Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel

Started: 10/1/2015

NCT01959841 Phase 3 COMPLETED

Phase III Study of ASP2151 in Herpes Zoster Patients

Started: 8/1/2013

NCT05214794 Phase 2 COMPLETED

An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis

Started: 4/20/2022

NCT02970331 Phase 2 WITHDRAWN

A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pefcalcitol Ointment, 0.005%, Applied Topically Twice Daily (BID) for 8 Weeks in Adolescent Subjects 12 to < 17 Years of Age With Plaque Psoriasis

Started: 6/1/2019

NCT03334240 Phase 2 TERMINATED

ICVT in HPV-induced Genital Lesions of Immunocompromised and Immunocompetent Patients

Started: 10/5/2017

NCT03091426 Phase 2 COMPLETED

Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis

Started: 3/8/2017

NCT02596074 Phase 2 COMPLETED

Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN

Started: 11/1/2015

NCT02849262 Phase 2 COMPLETED

Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts

Started: 7/1/2016

NCT02571998 Phase 2 COMPLETED

A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris

Started: 10/1/2015

NCT02333643 Phase 2 COMPLETED

A Phase 2 Efficacy Study of CLS003 ICVT in Subjects With Cutaneous Warts.

Started: 1/1/2015

NCT02456480 Phase 2 COMPLETED

Pharmacodynamics of Omiganan (CLS001) in Patients With Atopic Dermatitis

Started: 5/1/2015

NCT01301157 Phase 2 COMPLETED

Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis Patients

Started: 2/1/2011

NCT02066545 Phase 2 COMPLETED

Safety and Efficacy Study of CLS001Topical Gel Compared to Vehicle in Subjects With Inflammatory Acne Vulgaris

Started: 4/1/2014

NCT01784133 Phase 2 COMPLETED

A Twelve Week Safety and Efficacy Study in Rosacea

Started: 3/1/2013

NCT00980629 Phase 2 COMPLETED

Dose-Finding Study of M516102 in the Treatment of Pruritus Associated With Atopic Dermatitis

Started: 8/1/2008

NCT00884169 Phase 2 COMPLETED

Study to Investigate the Efficacy and the Safety of M518101 in Psoriasis Patients

Started: 7/1/2009

NCT03071679 Phase 1 COMPLETED

Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers

Started: 2/6/2017

NCT02106260 Phase 1 COMPLETED

First-in-Human Study of CLS003 ICVT in Subjects With Cutaneous Warts

Started: 3/1/2014

NCT02028286 Phase 1 COMPLETED

A 21 Day Pharmacokinetics Study in Papulopustular Rosacea

Started: 1/1/2014

Drug Candidates

nemolizumab ASP2151 ASP2151 placebo CLS006 CLS006 Vehicle CLS006 (Furosemide) Topical Gel Vehicle Topical Gel pefcalcitol ointment, 0.005% CLS001 (Omiganan) Vehicle
Activity Status: Stale
Last Trial Started: 4/20/2022
Last Trial Ended: 7/30/2024
Trials (12 months): 0
Completed Trials: 23
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.